Daniel Trachsel is a Swiss medicinal chemist who is known for working in the pharmaceutical industry and for studying and developing numerous psychedelics and other psychoactive drugs.
Biography Trachsel studied chemistry at the Burgdorf University of Applied Sciences. He became interested in psychoactive drugs in 1993, which coincided with the start of his training as a chemist.
Trachsel published his first book, Psychedelische Chemie Aspekte Psychoaktiver Moleküle (Psychedelic Chemistry: Aspects of Psychoactive Molecules), in 2000, which has undergone several revisions. He also published the book Phenethylamine: von der Struktur zur Funktion (Phenethylamines: From Structure to Function), co-authored with David Lehmann and Christoph Enzensperger, in 2013. According to Hamilton Morris and Nick Cozzi in mid-2023, this book is in the process of being translated into English. It is being translated by the Alexander Shulgin Research Institute (ASRI), with tentative publication by Transform Press, and is also independently being translated by chemist David Carlson.
Trachsel worked as a medicinal chemist at a biopharmaceutical company starting in 2002, including in areas like renin inhibitors and orexin receptor antagonists. He is the head of chemistry at ReseaChem GmbH, a chemical research laboratory, in Burgdorf, Switzerland.https://derhollaender.ch/wp-content/uploads/2017/05/Test-September-2017.pdf "ReseaChem GmbH. Chemical Research Laboratory. Daniel Trachsel, Head of Chemistry" [...] "ReseaChem GmbH, Pestalozzistrasse 16, CH-3400 Burgdorf" In addition to his books and papers, Trachsel has published various patents, including many on psychedelics with Matthias Liechti and others that have been assigned to Mind Medicine (now Definium Therapeutics).
Trachsel has developed and published on a large number of novel psychedelic and entactogen compounds, including their psychoactive effects. This has been in a manner similar to that of the psychedelic chemist Alexander Shulgin, which has caused Trachsel to sometimes be referred to as the "German Shulgin". However, unlike Shulgin, Trachsel has publicly distanced himself from self-experimentation. Trachsel has especially studied fluorinated and other phenethylamines, for instance the mescaline derivative trifluoromescaline (TFM), among many others.
Compounds Compounds that were first synthesized, tested in humans, and/or reported by Trachsel and colleagues include:
2Cs 2C-B-AN 2C-BI-8 2C-CN 2C-cP 2C-DB 2C-EF 2C-O-x (various) 2C-Ph (2C-BI-1) 2C-T-3 (2C-T-20) 2C-T-16 2C-T-19 2C-T-21.5 2C-T-22 2C-T-25 2C-T-27 2C-T-28 2C-T-30 2C-T-31 2C-T-32 2C-T-33 2C-tBu 2C-TFE 2C-V 2C-YN DOx DODB DOPF DOTFE DOTFM DOYN MALM MDFEM MFEM MIPM MMALM MTFEM N-Methyl-DOET 4Cs 4C-B Scalines 2-Methylmescaline 2,6-Dimethylmescaline Cycloproscaline (CP) Difluoroescaline (DFE) Difluoromescaline (DFM) Fluoroescaline (FE) Fluoroproscaline (FP) Isobuscaline (IB) Metadifluoromescaline (MDFM) Phescaline Tomscaline Trifluoroescaline (TFE) Trifluoromescaline (TFM) Trifluoroproscaline (TFP) Desoxyscalines Desoxybromoscaline (DBR) Others 3Cs 2-Bromo-TMA 3C-AL 3C-DFE 3C-FE 3C-FP 3C-MAL 3C-P 3C-TFE ψ-Phenethylamines 2,4,6-TMPEA (ψ-2C-O) ψ-2C-DFMO ψ-DODFMO BOx and related BMB BOED BOHB N-Benzylphenethylamines NBOMe-mescaline MDxx 3C-BOH 6-Chloro-MDA 6-Methyl-MDA DFMDA (F2-MDA) DFMDMA (F2-MDMA) Lysergamides CYP-LAD (TRALA-22) TRALA-12 (likely didehydro-LSD or DDH-LSD) Others
Selected publications Books [Note: There are also several subsequent editions (2nd (2002) through 5th (2016)).]
Papers
See also List of psychedelic chemists
References